JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.
"We are pleased to welcome Doug Pace to our leadership team as we further implement Dyadic's corporate development strategy. We continue to see strong interest in and adoption of our C1 platform for pharmaceutical applications, internal product opportunities such as recombinant albumin, and our Dapibus™ platform for non-pharmaceutical applications, in areas such as nutrition and health with products like recombinant casein proteins for the dairy market. We anticipate Doug's strong background in specialty biopharmaceuticals will help facilitate the expansion of our business development efforts across our core verticals", said Joseph Hazelton, Chief Business Officer for Dyadic.
"The broad utility of the C1 and Dapibus™ platforms has the potential to transform biomanufacturing by leveraging the industrial heritage of Dyadic to make affordable, high-quality recombinant proteins ...